Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26174755 | 0.92 | MAP3K11 (0.49) | TNIKKITMAP3K11NTRK1KDM4E | |
| SCHEMBL26174756 | 0.91 | KIT (0.51) | KITMAP3K11NTRK1 | |
| SCHEMBL26174717 | 0.89 | ALDH1A1 (0.41) | TNIKKITMAP3K11NTRK1KDM4E | |
| SCHEMBL26174672 | 0.89 | JAK2 (0.44) | TNIKKITMAP3K11NTRK1 | |
| SCHEMBL30400480 | 0.88 | KIT (0.47) | TNIKKITMAP3K11CAMKK2RIPK1 | |
| SCHEMBL26175305 | 0.88 | KIT (0.47) | TNIKKITMAP3K11CAMKK2RIPK1 | |
| SCHEMBL26175265 | 0.87 | CAMKK2 (0.52) | TNIKCAMKK2RIPK1 | |
| SCHEMBL26174978 | 0.87 | MAP3K11 (0.50) | TNIKMAP3K11 | |
| SCHEMBL26175353 | 0.87 | ALK (0.47) | TNIKKITMAP3K11 | |
| SCHEMBL30400156 | 0.86 | NTRK1 (0.44) | TNIKKITMAP3K11NTRK1CAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4415817-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | claimed |
| WO-2023064349-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | TNIK 500/4885KIT 4356/4885MAP3K11 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.